Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States

Background: Despite advances in tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia in chronic phase (CML-CP), a sizeable proportion of patients with CML-CP remains refractory or intolerant to these agents. Objectives: Treatment patterns, healthcare resource utilization (HRU), and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Atallah, Ehab L., Maegawa, Rodrigo, Latremouille-Viau, Dominick, Rossi, Carmine, Guérin, Annie, Wu, Eric Q., Patwardhan, Pallavi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352872/
https://www.ncbi.nlm.nih.gov/pubmed/35979528
http://dx.doi.org/10.36469/001c.36975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9352872/
https://www.ncbi.nlm.nih.gov/pubmed/35979528
http://dx.doi.org/10.36469/001c.36975

Ejemplares similares